Aleksandr Ianevski
Overview
Explore the profile of Aleksandr Ianevski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ianevski A, Froysa I, Lysvand H, Calitz C, Smura T, Nilsen H, et al.
Antiviral Res
. 2024 Feb;
224:105842.
PMID: 38417531
Enteroviruses are a significant global health concern, causing a spectrum of diseases from the common cold to more severe conditions like hand-foot-and-mouth disease, meningitis, myocarditis, pancreatitis, and poliomyelitis. Current treatment...
12.
Benjakul S, Anthi A, Kolderup A, Vaysburd M, Lode H, Mallery D, et al.
PNAS Nexus
. 2023 Dec;
2(12):pgad403.
PMID: 38077689
Immunocompromised patients often fail to raise protective vaccine-induced immunity against the global emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Although monoclonal antibodies have been authorized for clinical...
13.
Chen Y, He L, Ianevski A, Ayuda-Duran P, Potdar S, Saarela J, et al.
Nat Protoc
. 2023 Nov;
19(1):60-82.
PMID: 37996540
Most patients with advanced malignancies are treated with severely toxic, first-line chemotherapies. Personalized treatment strategies have led to improved patient outcomes and could replace one-size-fits-all therapies, yet they need to...
14.
Ravlo E, Ianevski A, Starheim E, Wang W, Ji P, Lysvand H, et al.
Int J Infect Dis
. 2023 Oct;
137:75-78.
PMID: 37852599
Vaccinated convalescents do not develop severe COVID-19 after infection with new SARS-CoV-2 variants. We questioned how messenger RNA (mRNA) vaccination of convalescents provides protection from emerging virus variants. From the...
15.
Potdar S, Ianevski F, Ianevski A, Tanoli Z, Wennerberg K, Seashore-Ludlow B, et al.
Nucleic Acids Res
. 2023 May;
51(W1):W57-W61.
PMID: 37178002
Functional precision medicine (fPM) offers an exciting, simplified approach to finding the right applications for existing molecules and enhancing therapeutic potential. Integrative and robust tools ensuring high accuracy and reliability...
16.
Otte M, Stachelscheid J, Glass M, Wahnschaffe L, Jiang Q, Lone W, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173993
T-prolymphocytic leukemia (T-PLL) is a rare and mature T-cell malignancy with characteristic chemotherapy-refractory behavior and a poor prognosis. Molecular concepts of disease development have been restricted to protein-coding genes. Recent...
17.
Murumagi A, Ungureanu D, Khan S, Arjama M, Valimaki K, Ianevski A, et al.
Br J Cancer
. 2022 Dec;
128(4):678-690.
PMID: 36476658
Many efforts are underway to develop novel therapies against the aggressive high-grade serous ovarian cancers (HGSOCs), while our understanding of treatment options for low-grade (LGSOC) or mucinous (MUCOC) of ovarian...
18.
Ianevski A, Ahmad S, Anunnitipat K, Oksenych V, Zusinaite E, Tenson T, et al.
Cell Mol Life Sci
. 2022 Nov;
79(12):605.
PMID: 36436108
The viral epidemics and pandemics have stimulated the development of known and the discovery of novel antiviral agents. About a hundred mono- and combination antiviral drugs have been already approved,...
19.
Ravindran V, Wagoner J, Athanasiadis P, den Hartigh A, Sidorova J, Ianevski A, et al.
Brief Bioinform
. 2022 Oct;
23(6).
PMID: 36305426
The ongoing coronavirus disease 2019 (COVID-19) pandemic has highlighted the need to better understand virus-host interactions. We developed a network-based method that expands the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-host...
20.
Ravlo E, Evensen L, Sanson G, Hildonen S, Ianevski A, Skjervold P, et al.
Viruses
. 2022 Oct;
14(10).
PMID: 36298676
Some viruses cause outbreaks, which require immediate attention. Neutralizing antibodies could be developed for viral outbreak management. However, the development of monoclonal antibodies is often long, laborious, and unprofitable. Here,...